ZyVersa Therapeutics, Inc.
ZVSA
$0.6794
-$0.0306-4.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.84M | -9.41M | -21.33M | -21.83M | -97.58M |
| Total Depreciation and Amortization | 4.30K | 6.90K | -98.80K | 18.20K | 10.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 760.20K | 916.90K | 12.70M | 12.69M | 87.62M |
| Change in Net Operating Assets | 2.52M | 929.90K | -391.90K | -288.40K | 2.04M |
| Cash from Operations | -5.56M | -7.56M | -9.12M | -9.41M | -7.91M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.87M | 6.54M | 8.50M | 10.74M | 21.75M |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | -7.20K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | 0.00 | -230.00K | -10.70M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -735.10K | -588.00K | -833.60K | -1.20M | -2.39M |
| Cash from Financing | 5.13M | 5.95M | 7.67M | 9.31M | 8.66M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | 0.00 | 0.00 |
| Net Change in Cash | -422.10K | -1.61M | -1.46M | -109.20K | 755.50K |